Skip to main content

Table 2 Univariate and multivariate analysis of clinical and pathologicalal response rates by biological factors

From: Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT)

Factors Univariate analysis Multivariate analysis
OR 95%CI P-value OR 95%CI P-value
age (years)
  ≤ 45 Ref      
  > 45 0.792 0.394–1.593 0.513    
BMI (kg/m2)
  < 25 Ref      
  ≥ 25 1.384 0.617–3.102 0.430    
Menopausal status
 Postmenopausal Ref      
 Premenopausal 1.130 0.569–2.245 0.726    
Multifocality
 Multifocal Ref      
 Unifocal 0.821 0.353–1.911 0.648    
Local invasion
 Yes Ref      
 No 0.432 0.051–3.690 0.443    
LVI
 Absent Ref      
 Present 0.292 0.106–0.800 0.017 0.314 0.108–0.918 0.034
Clinical tumor size
 T1 Ref      
 T2 0.762 0.267–2.173 0.533    
 T3 0.948 0.255–3.525 0.875    
Lymph node status
 N0 Ref      
 N1–2 1.185 0.560–2.507 0.657    
Histological grade
 I-II Ref      
 III 1.427 0.667–3.054 0.360    
Histologic type
 IDC Ref.   .    
 Others 4.889 0.617–38.739 0.133    
Progesterone receptor
 Negative Ref.   .    
 Positive 0.451 0.222–0.917 0.028    
Estrogen receptor
 Negative Ref    Ref   
 Positive 0.286 0.118–0.694 0.006 0.342 0.132–0.889 0.028
Hormone receptor
 Negative Ref      
 Positive 0.497 0.246–1.002 0.051    
HER2
 Negative Ref      
 Positive 1.833 0.914–3.678 0.088    
Ki67
  ≤ 60% Ref.   . Ref   
  > 60% 0.363 0.175–0.751 0.006 0.258 0.106–0.627 0.003
Molecular subtype
 Luminal B Ref.   .    
 HER2 enriched 0.072 0.016–0.324 0.001    
 Triple negative 0.711 0.331–1.527 0.046    
NCT regimen
 TEC Ref    Ref   
 TCbH 2.228 1.103–4.501 0.025 3.268 1.380–7.738 0.007
NCT time, cycles
  ≤ 4 Ref.   .    
  > 4 0.390 0.127–1.196 0.100    
Hemoglobin(g/L)
  ≤ 120 Ref      
  > 120 0.359 0.140–0.923 0.033 0.423 0.154–0.988 0.046
  1. Abbreviations: OR odds ratio, CI confidence interval, BMI body mass index, pCR pathologic complete response, NCT Neoadjuvant chemotherapy, IDC Invasive ductal carcinoma, HER2 Human epidermal growth factor receptor, LVI lymphovascular invasion, Others: invasive lobular carcinoma, metaplastic carcinoma and medullary carcinoma
\